|
|
mesoporous silica nanoparticle |
|
Vaxjo ID |
315 |
|
Vaccine Adjuvant Name |
mesoporous silica nanoparticle |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
A plain mesoporous silica (MS) nanoparticle without any immunomodulatory molecules that enhances anti-cancer immunity in vivo, promoting both Th1 and Th2 immune responses and enhancing the effector memory of CD4(+) and CD8(+) T cell populations in the bone marrow, lymph node, and spleen of mice. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
A plain mesoporous silica (MS) nanoparticle |
|
Structure |
mesoporous silica (MS) nanoparticle |
|
Function |
A plain mesoporous silica (MS) nanoparticle without any immunomodulatory molecules enhances anti-cancer immunity in vivo. On page 1169, X.P. Wang, N. M. Tsuji, A. Ito and co-workers show that a plain MS nanoparticle promotes both Th1 and Th2 immune responses, and enhances the effector memory of CD4(+) and CD8(+) T cell populations in the three most important immune organs (bone marrow, lymph node and spleen) of mice. |
| Related Vaccine(s) |
|
| References |
Wang et al., 2016: Wang X, Li X, Yoshiyuki K, Watanabe Y, Sogo Y, Ohno T, Tsuji NM, Ito A. Cancer Immunotherapy: Comprehensive Mechanism Analysis of Mesoporous-Silica-Nanoparticle-Induced Cancer Immunotherapy (Adv. Healthcare Mater. 10/2016). Advanced healthcare materials. 2016; 5(10); 1246. [PubMed: 27226038].
|
|
